GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Price-to-Owner-Earnings

ORKA (Oruka Therapeutics) Price-to-Owner-Earnings : (As of May. 15, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Price-to-Owner-Earnings?

As of today (2025-05-15), Oruka Therapeutics's share price is $9.71. Oruka Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Oruka Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


ORKA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 28.9
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-05-15), Oruka Therapeutics's share price is $9.71. Oruka Therapeutics does not have enough years/quarters to calculate the Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024. Therefore GuruFocus does not calculate PE Ratio (TTM) at this moment.

As of today (2025-05-15), Oruka Therapeutics's share price is $9.71. Oruka Therapeutics does not have enough years/quarters to calculate the EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024. Therefore GuruFocus does not calculate PE Ratio without NRI at this moment.


Oruka Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Oruka Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Price-to-Owner-Earnings Chart

Oruka Therapeutics Annual Data
Trend Dec24
Price-to-Owner-Earnings
-

Oruka Therapeutics Semi-Annual Data
Dec24
Price-to-Owner-Earnings -

Competitive Comparison of Oruka Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Oruka Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oruka Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Price-to-Owner-Earnings falls into.


;
;

Oruka Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Oruka Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=9.71/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oruka Therapeutics  (NAS:ORKA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Oruka Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.